Search

01/02/2023 Immune thrombotic thrombocytopenic purpura: clinical suspicion and basic management in emergency departments - an expert review and consensus statement from the Spanish societies of hematology and hemotherapy (SEHH) and emergency medicine (SEMES)
Pascual-Izquierdo, C, Salmeron, PP, Ruiz, FT, Ferreiras, DV, Hernandez, SJ, Argente, RS, Galan, CD, Comos, JD. Immune thrombotic thrombocytopenic purpura: clinical suspicion and basic management in emergency departments - an expert review and consensus statement from the Spanish societies of hematology and hemotherapy (SEHH) and emergency medicine (SEMES). EMERGENCIAS. 2023; 35(1)DOI:. PMID:36756916. IF:5.400(Q1/1D).
01/12/2021 Characteristics of isolated superficial vein thrombosis and diagnostic-therapeutic management in Spanish hospital emergency departments: the ALTAMIRA study
Chaib, FB, Hernandez, SJ, Navas, JMP, Mancilla, JC, Arias, LC, Loranca, MM, Gomez, AP, Marquez, AA, Polo, LP, Garrido-Lestache, AS, Lecumberri, R, Artacho, PR. Characteristics of isolated superficial vein thrombosis and diagnostic-therapeutic management in Spanish hospital emergency departments: the ALTAMIRA study. EMERGENCIAS. 2021; 33(6)DOI:. PMID:34813190. IF:5.345(Q1/2D).
01/08/2024 Prophylaxis of venous thromboembolism in hospitalized patients admitted from Spanish emergency departments: the PROTESU II study
Díaz, CR, Hernández, SJ, Chaib, FB, Abanto, AIC, Ayaso, MC, Polo, LL, Torrecillas, LG, Valle, HA, Velilla, MO, Jiménez, D, Lecumberri, R, Artacho, PR. Prophylaxis of venous thromboembolism in hospitalized patients admitted from Spanish emergency departments: the PROTESU II study. EMERGENCIAS. 2024; 36(4)DOI:10.55633/s3me/051.2024. PMID:39234833. IF:6.300(Q1/1D).
01/01/2022 Características sociodemográficas, funcionales y consumo de recursos de la población mayor atendida en los servicios de urgencias españoles: una aproximación desde la cohorte EDEN
Miró Ò., Jacob J., García-Lamberechts E.J., Salmerón P.P., Llorens P., Jiménez S., Burillo-Putze G., Montero-Pérez F.J., Aguiló S., Gil-Rodrigo A., Alonso C.F., Alquézar-Arbé A., Parra-Esquivel P., Bayarri M.J.F., Tejera M.G., Soria J.M., Cirera I., Adroher M., Mojarro E.M., García E.G., Valle B., Salado Á.D., Grispán M.R., Díez M.P.L., Chaib F.B., Mota M.S., García J.P., Sindín G.S., González R.J., Pérez Costa R.A., Sánchez C.E., Zapico A.P., Del Castillo J.G.. Características sociodemográficas, funcionales y consumo de recursos de la población mayor atendida en los servicios de urgencias españoles: una aproximación desde la cohorte EDEN. EMERGENCIAS. 2022; 34(6)DOI:. PMID:36625691. IF:5.500(Q1/2D).
01/01/2022 El anciano frágil en urgencias: principales retos
Puig-Campmany M., Ris-Romeu J.. El anciano frágil en urgencias: principales retos. EMERGENCIAS. 2022; 34(6)DOI:. PMID:36625690. IF:5.500(Q1/2D).
01/01/2026 Current use and perspectives of PET imaging in Alzheimer's disease: A Spanish national survey
Cabrera-Martín, MN, Aguiar-Fernández, P, Camacho-Martí, V, Guillén-Valderrama, EF, Jiménez-Bonilla, JF, Lojo-Ramírez, JA, López-Mora, DA, Matías-Guiu, JA, Paredes-Rodríguez, P, Perissinotti, A, Arbizu, J. Current use and perspectives of PET imaging in Alzheimer's disease: A Spanish national survey. Journal Of Alzheimers Disease Reports. 2026; 10DOI:10.1177/25424823261437129. PMID:. IF:(Q/D).
01/03/2024 Guselkumab-Treated Patients with Plaque Psoriasis Who Achieved Complete Skin Clearance for = 156 Consecutive Weeks: A Post-Hoc Analysis From the VOYAGE 1 Clinical Trial
Puig L, Costanzo A, de Jong EMGJ, Torres T, Warren RB, Wapenaar R, Wegner S, Gorecki P, Gramiccia T, Jazra M, Buyze J, Conrad C. Guselkumab-Treated Patients with Plaque Psoriasis Who Achieved Complete Skin Clearance for = 156 Consecutive Weeks: A Post-Hoc Analysis From the VOYAGE 1 Clinical Trial. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY. 2024; 25(2)DOI:10.1007/s40257-023-00816-1. PMID:37804472. IF:8.800(Q1/1D).
01/02/2024 Brodalumab Versus Guselkumab in Patients with Moderate-to-Severe Psoriasis with an Inadequate Response to Ustekinumab: A Randomized, Multicenter, Double-Blind Phase 4 Trial (COBRA)
Reich, K, Bianchi, L, Khemis, A, Maul, JT, Tsianakas, A, Schempp, CM, Petersen, K, Noergaard, MM, Puig, L. Brodalumab Versus Guselkumab in Patients with Moderate-to-Severe Psoriasis with an Inadequate Response to Ustekinumab: A Randomized, Multicenter, Double-Blind Phase 4 Trial (COBRA). Dermatology and Therapy. 2024; 14(2)DOI:10.1007/s13555-023-01092-x. PMID:38300408. IF:4.200(Q1/1D).